The poop on Glaxo chimp virus project
From ANIMAL PEOPLE, July-August 2013:
LONDON––GlaxoSmithKline, the largest British pharmaceuticals maker, “is betting on a new vaccine technology based on chimpanzee viruses by acquiring Swiss-based Okairos for 250 million euros ($321 million),” Ben Hirschler of Reuters reported on May 29, 2013. Read more